Drug
Lutetium Lu 177 dotatate clinical trials
Also written Lutathera and 177Lu-DOTATATE.
- studies test it
- 46
- open now
- 17
- in phase 3
- 6
- first study started
- 2004
Keep track of what changes. Save the lutetium Lu 177 dotatate studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Development codes
Other names
Combined with it in one product
Studies by the year they started
46 studies that test it; most in 2020 (9)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 9 |
| 2021 | 4 |
| 2022 | 2 |
| 2023 | 7 |
| 2024 | 7 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 13
- Phase 2
- 29
- Phase 3
- 6
- Phase 4
- 1
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 41
National Cancer Institute (NCI) (6) · Novartis Pharmaceuticals (2) · Advanced Accelerator Applications (2) · Jules Bordet Institute (2) · Fundación de investigación HM (2) · Alliance for Clinical Trials in Oncology (1) · NYU Langone Health (1) · Stanford University (1)
Often tested with
Tested in the same studies.
64Cu-DOTATATE (2) · Olaparib (2) · Capecitabine (1) · Temozolomide (1) · Lutetium-177 (1) · Metoclopramide (1) · Triapine (1) · Gallium Ga 68 dotatate (1)
Studies
Open first, then newest update. How each study uses lutetium Lu 177 dotatate is read from its arms, and is right about nine times in ten.
Testing it · 46
- Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine TumorsRecruitingPhase 1National Cancer Institute (NCI)NCT05687123Written as Lutetium Lu 177 Dotatate
- Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine TumorsRecruitingPhase 2National Cancer Institute (NCI)NCT04665739Written as Lutetium Lu 177 Dotatate
- Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05773274Written as Lutetium Lu 177 Dotatate
- Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine CellsRecruitingPhase 2National Cancer Institute (NCI)NCT05691465Written as Lutetium Lu 177 Dotatate
- Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation TherapyRecruitingPhase 2Mayo ClinicNCT04082520Written as Lutetium Lu 177 Dotatate
- Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell CancerRecruitingPhase 2Weill Medical College of Cornell UniversityNCT05583708Written as Lutetium Lu 177 dotatate
- Lutathera for Treatment of Recurrent or Progressive High-Grade CNS TumorsRecruitingPhase 1/2Nationwide Children's HospitalNCT05278208Written as LUTATHERA® (Lutetium Lu 177 dotatate)
- Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine TumorsRecruitingPhase 4Vanderbilt-Ingram Cancer CenterNCT06016855Written as Lutetium Lu 177 Dotatate
- 177Lu-DOTATATE for Recurrent MeningiomaRecruitingPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT06326190Written as 177Lu-DOTATATE
- 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast CancerRecruitingPhase 2OHSU Knight Cancer InstituteNCT04529044Written as Lutetium Lu 177 Dotatate
- Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NETRecruitingPhase 2Institut du Cancer de Montpellier - Val d'AurelleNCT04954820Written as Lutathera
- Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).RecruitingPhase 1/2Fundación de investigación HMNCT06607692Written as Olaparib; 177Lu-DOTATATE
- Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.RecruitingPhase 1Emory UniversityNCT07150546Written as Lutetium Lu 177 Dotatate
- 177Lu-DOTATATE Modified Delivery Based on Individualized DosimetryRecruitingPhase 2University of IowaNCT06395402Written as Lutetium Lu 177 dotatate therapy
- A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETsRecruitingPhase 3HTA Co., Ltd.NCT07057622Written as 177Lu-DOTATATE injection
- 177Lutetium-DOTATATE in Children with Primary Refractory or Relapsed High-risk NeuroblastomaRecruitingPhase 2Jakob StenmanNCT04903899Written as 177Lu-DOTATATE
- Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed IndicationsNot yet recruitingPhase 2University College, LondonNCT06121271Written as Lu-177 DOTATATE (Lutathera®)
- Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET TrialActive, not recruitingPhase 2Alliance for Clinical Trials in OncologyNCT05247905Written as Lutetium Lu 177 Dotatate
- NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.Active, not recruitingPhase 1Novartis PharmaceuticalsNCT06379217Written as [177Lu]Lu-DOTA-TATE
- Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk MeningiomaActive, not recruitingPhase 2NYU Langone HealthNCT03971461Written as Lutathera
See all 46 studies that test lutetium Lu 177 dotatate →
Given in every arm · 6 — lutetium Lu 177 dotatate is usual care beside what is tested
- Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine TumorsRecruitingPhase 1University of ChicagoNCT06663072Written as 177Lu-DOTATATE
- A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.Active, not recruitingPhase 1Novartis PharmaceuticalsNCT05109728Written as [177Lu]Lu-DOTA-TATE
- Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver MetastasesCompletedPhase 2Nicholas Fidelman, MDNCT03457948Written as Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate
- Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine TumorsActive, not recruitingPhase 2National Cancer Institute (NCI)NCT05724108Written as Lutetium Lu 177 Dotatate
- Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor PatientsTerminatedPhase 2Erasmus Medical CenterNCT07012330Written as 177Lu-DOTATATE
- A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine TumorsWithdrawnPhase 1/2David BushnellNCT04614766Written as Lutathera
Codes
What other systems call lutetium Lu 177 dotatate · ClinicalTrials.gg INT004424
- MeSH (NLM) C447941lutetium Lu 177 dotatateConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) AE221IM3BBLUTETIUM OXODOTREOTIDE LU-177Confirmed FDA, NLM
- RxNorm 1999335One source FDA
- NCI Thesaurus C95020Lutetium Lu 177 DotatateOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C447941 | lutetium Lu 177 dotatate | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | AE221IM3BB | LUTETIUM OXODOTREOTIDE LU-177 | Confirmed FDA, NLM |
| RxNorm | 1999335 | — | One source FDA |
| NCI Thesaurus | C95020 | Lutetium Lu 177 Dotatate | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.